glp-1 gip lilly LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes Understand GLP-1/GIP Dual Agonist Tirzepatide

Description

About one in 5 women in this age group has used GLP-1 medications, the highest rate of any age group

Cell 155(6):14221434

Wegovy may make a patients body collect more of the contrast used for CT scans and PET scans

The resulting concordance between the emulated and actual SUSTAIN-6 and SURPASS-CVOT trial estimates strengthen confidence in the internal validity of our findings for the successfully assessed endpoints

March 3, 2025: Go-Forward Plan in Ozempic Lawsuits Discussed During Status Hearing In a recent status conference for the Ozempic group lawsuit, Judge Karen Spencer Marston discussed a number of important milestones for GLP-1 lawsuits in 2025